Published in Lab Business Week, February 19th, 2006
The company was formed with a novel, clinical-stage migraine molecule licensed from Eli Lilly & Co. and a portfolio of preclinical assets based on a robust bifunctional neuromodulator chemistry platform, which originated at Sention, Inc. Pappas Ventures seed-funded and formed the company.
The series A financing was co-led by Domain Associates and Pappas Ventures with other investors including Triathlon Medical Ventures and Pearl Street Venture Funds.
The series A funding...
Want to see the full article?
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Lab Business Week
NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.